Metraipolis › archive › dc_a3ce20097e7d
Trends and characteristics during 17 years of naloxone distribution and administration through an overdose prevention program in Pittsburgh, Pennsylvania — Europe PMC PMID:41134828
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41134828
- DOI
- 10.1371/journal.pone.0315026
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-08T00:23:24.749Z
- SHA-256 of the archived text
85863866301c3203754e6c48a9a08d592f2663bb7c88e462f8cdf3f1b57e8cc4- Stable URL of this page
https://metraipolis.com/documento/dc_a3ce20097e7d
How to cite
Trends and characteristics during 17 years of naloxone distribution and administration through an overdose prevention program in Pittsburgh, Pennsylvania — Europe PMC PMID:41134828 — Europe PMC (en), https://europepmc.org/article/MED/41134828 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_a3ce20097e7d (Metraipolis archive dc_a3ce20097e7d, sha256 85863866301c3203754e6c48a9a08d592f2663bb7c88e462f8cdf3f1b57e8cc4)
BibTeX
@misc{dca3ce20097e7d,
title = {Trends and characteristics during 17 years of naloxone distribution and administration through an overdose prevention program in Pittsburgh, Pennsylvania — Europe PMC PMID:41134828},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41134828},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_a3ce20097e7d; sha256 85863866301c3203754e6c48a9a08d592f2663bb7c88e462f8cdf3f1b57e8cc4},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/41134828. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Objective: Describe time trends during 17.5 years of community-based naloxone distribution. Methods: Analysis of administrative records from a harm reduction program in Pittsburgh, Pennsylvania, USA, collected during encounters for overdose education, naloxone dispensing and refills. Monthly time trends were analyzed using segmented regression. Programmatic context aided interpretation of quantitative findings. We also evaluated impacts of 2014 state legislation loosening naloxone prescribing requirements and providing Good Samaritan protections. Results: From July 2005 to January 2023 there were 16,904 service encounters by 7,582 unique participants, resulting in 70,234 naloxone doses dispensed, with 5,521 overdose response events (OREs), utilizing 8,756 naloxone doses. After legislation, new participants increased from 10.4 to 65.9 per month. New participants tended to be older (46 vs. 37 years), female (58% to 35%), White race, and more likely to be family/friends as opposed to people who use drugs themselves. Consequently, ORE per participant fell from 1.46 to 0.47 in the year after enactment. On average, 1.63 (95% CI: 1.60, 1.65) naloxone doses were administered per ORE, which did not change substantially over 17 years (χ2 = 0.28, 3 df, p = 0.60) during evolution from prescription opioids, to heroin, to illicitly manufactured fentanyl. In 98.0% of OREs the person who experienced overdose "was okay", i.e., survived. Emergency medical services were called in 16% of OREs overall, but <7% since 2019. There were 106 more emesis events per 1,000 OREs with 4 mg nasal spray compared to intramuscular injection; and 48 per 1,000 more reports of anger. Titration of intramuscular naloxone was associated with lower rates of adverse events. Conclusions: While state legislation created the environment for expansion, reaching previously underserved communities required intentional new programmatic development and outreach. Long-term consistency of <2 doses per ORE, high survival rate, and robust utilization all lend confidence in prioritizing naloxone distribution directly to people who use drugs and their social networks. Trial registration: This investigation was pre-registered https://osf.io/b2f4h. Tema degli esploratori: ricerca e scienza aperta (ricerca Europe PMC «open science», solo open access). Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-10-24). Identificativi: PMID 41134828 · PMCID PMC12551907 · DOI 10.1371/journal.pone.0315026. Descrittori MeSH principali: Naloxone; Narcotic Antagonists; Drug Overdose. Pagina: https://europepmc.org/article/MED/41134828 — https://doi.org/10.1371/journal.pone.0315026. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-08T00:01:05.919Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.